Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 6, 2004

View Archived Issues

Comparison of the gastric safety of valdecoxib and naproxen in elderly volunteers

Three series of COX-2 inhibitors designed at Almirall Prodesfarma

BMS scientists present two novel series of factor VIIa inhibitors

Therapeutic benefits of omalizumab in allergy conjunctivitis

New pharmacokinetic data for ramelteon presented at the ACCP meeting

Two novel series of chemokine CCR2 antagonists identified at BMS

Novel anti-HCV agents targeting NS3-NS4A protease claimed by Enanta

Three series of GSK-3beta inhibitors in early development at Sanofi-Synthelabo

Japanese team describes flavonoids acting at aldose reductase, AGE formation and free radicals

Selective topoisomerase I poison for cancer therapy

Combination treatment with Abbott PARP inhibitor and doxorubicin increases life span

Analogues of antiangiogenic agent NM-3 show enhanced antiproliferative activity in vivo

Human monoclonal antibody promising against SARS in vivo

Provensis continues work to lift Varisolve clinical hold

SkyePharma and Merck KGaA revise agreement for phase III project

European submission seeks approval of Dacogen for MDS

Positive safety data from phase I/II study of HuMax-EGFr

New phase II study for SDX-101 in CLL commences enrollment

NABTT studies SDX-102 for brain tumors

Medarex receives NIAID grants to develop MDX-1303 for anthrax infection

European approval for Protelos

No cardiovascular issues in long-term studies of Celebrex

Dose-ranging study for premature ejaculation compound LI-301

TACI-Ig cleared to enter phase Ib studies in advanced B-cell malignancies

Phase III trial of Ikomio for ALS fails to show survival benefit

Entecavir submitted for U.S., European marketing approval for hepatitis B

Pro-Pharmaceuticals presents an update on the clinical development of Davanat-1 in cancer

Therapeutic effects of HepeX-B in patients with chronic HBV infection

A clinical trial confirms the antibacterial efficacy of telavancin in cSSTI

Apidra receives European approval

Febuxostat pharmacokinetics, pharmacodynamics and safety studied

Antitumor activity of EXEL-7647 observed in vivo

EXEL-0999 active in solid tumor and leukemia models

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 20, 2026.
Biohaven reports details on discovery of BHV-2100
BioWorld Science
Transient receptor potential melastatin 3 (TRPM3) is a calcium-permeable TRP channel that is highly expressed in somatosensory neurons, including nociceptors of...
Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’
BioWorld
The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
New GABA(B) receptor PAMs revealed in Addex Pharma patents
BioWorld Science
Addex Pharma SA has disclosed new GABA(B) receptor positive allosteric modulators (PAMs) potentially useful for the treatment of chronic cough, urinary...
Novel caspase-2 inhibitor shows in vivo neuroprotective effects
BioWorld Science
Caspase-2-mediated cleavage of tau at Asp314 generates a neurotoxic fragment, Δtau314, that drives early synaptic dysfunction in Alzheimer’s disease (AD) and...